In a phase 3 trial of 1030 patients with ARPI-pretreated, chemotherapy-naive mCRPC, adding nivolumab to docetaxel did not improve median radiographic PFS (9.4 vs 8.7 months; HR 0.96) or overall survival (18.7 vs 18.9 months); serious treatment-related events were 21% vs 15%.
RCTn = 1,030
Fizazi et al. Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial